{"prompt": "['MitraClip NT System', 'Clinical Investigation Plan Version: 1.0', 'Abbott', 'Table of Contents', '1.0 INTRODUCTION', '8', '1.1 Background and Rationale', '9', '1.2 Rationale for Conducting this Clinical Investigation', '10', '2.0 CLINICAL INVESTIGATION OVERVIEW', '11', '2.1 Clinical Investigation Overview', '11', '2.2 Devices To Be Used in the Clinical Investigation', '11', '2.2.1 Name of the Devices Under Investigation', '11', '2.2.2 Indication for Use', '14', '2.2.3 Description of the Devices Under Investigation', '15', '2.2.4 Summary of Previous Clinical Studies', '22', '2.2.5 Description of the Control Devices', '27', '2.2.6 Device Handling', '28', '3.0 CLINICAL INVESTIGATION DESIGN', '28', '3.1 Clinical Investigation Procedures and Follow-up Schedule', '28', '3.2 Early Termination or Suspension of the Clinical Investigation', '28', '4.0 ENDPOINTS', '29', '4.1 Primary Endpoint', '29', '4.2 Descriptive Endpoints', '30', '5.0 SUBJECT SELECTION AND WITHDRAWAL', '31', '5.1 Subject Population', '31', '5.2 Subject Screening', '31', '5.2.1 Subject Screening', '31', '5.2.2 Informed Consent', '32', '5.2.2.1 Special Circumstances for Informed Consent', '33', '5.3 Eligibility Criteria', '33', '5.3.1 General Eligibility Criteria', '33', '5.3.2 Inclusion Criteria', '34', '5.3.2.1 General Inclusion Criteria', '34', '5.3.3 Exclusion Criteria', '34', '5.3.3.1 General Exclusion Criteria', '34', 'Page 4 from 61']['MitraClip NT System', 'Clinical Investigation Plan Version: 1.0', 'Abbott', '5.4 Subject Enrollment', '35', '5.4.1 Subject Registration', '35', '5.6 Subject Withdrawal', '35', '5.7 Number of Subjects', '36', '5.8 Total Expected Duration of the Clinical Investigation', '36', '6.0 TREATMENT AND EVALUATION OF ENDPOINTS', '36', '6.1 Baseline/Pre-procedure/Pre-treatment', '36', '6.2 Schedule of Events', '41', '7.0 Adverse Events', '42', '7.1 Definition', '43', '7.1.1 Adverse Event', '43', '7.1.2 Serious Adverse Event', '43', '7.1.3 Device Deficiency/Device Malfunction', '44', '7.2 Device Relationship', '44', '7.2.1 Unanticipated (Serious Adverse) Device Effect', '44', '7.3 Adverse Event and Device Deficiency/Device Malfunction Reporting', '44', '7.3.1 Adverse Event Reporting', '44', '7.3.2 Unanticipated Serious Adverse Device Effect Reporting to Sponsor and IRB', '45', '7.3.3 Device Deficiency/Malfunction Reporting', '45', '7.3.4 Adverse Event Reporting to Country Regulatory Authorities by the Sponsor', '46', '8.0 Statistical Considerations', '46', '8.1 Analysis Populations', '46', '8.2 Rationale for Sample Size and Assumptions', '46', '8.3 Statistical Analysis', '47', '8.4 Timing of Analysis', '47', '8.5 Subgroup Analysis', '47', '9.0 DIRECT ACCESS TO SOURCE DATA/DOCUMENTS', '47', '10.0 QUALITY CONTROL AND QUALITY ASSURANCE', '47', '10.1 Selection of Clinical Sites and Investigators', '47', '10.2 Clinical Investigation Finances and Agreements', '47', '10.3 CIP Amendments', '48', '10.4 Training', '48', '10.4.1 Site Training', '48', 'Page 5 from 61']['MitraClip NT System', 'Clinical Investigation Plan Version: 1.0', 'Abbott', '10.4.2 Training Required for the Use of the Device', '48', '10.5 Monitoring', '48', '10.6 Deviations from CIP', '49', '10.7 Quality Assurance Audit', '49', '11.0 DATA HANDLING AND RECORD KEEPING', '50', '11.1 Protection of Personally Identifiable Information', '50', '11.2 Data Management Plan', '50', '11.3 Source Documentation', '51', '11.4 Case Report Form Completion', '51', '11.5 Record Retention', '51', '11.6 Investigational Devices Accountability', '51', '12.0 ETHICAL CONSIDERATION', '52', '13.0 CLINICAL INVESTIGATION CONCLUSION', '52', '14.0 PUBLICATION POLICY', '52', '15.0 Risk Analysis', '53', 'APPENDIX I: REFERENCES', '54', 'Page 6 from 61']\n\n###\n\n", "completion": "END"}